Recent Updates — BKYI
BIO-KEY International stockholders approved Proposal 4 at the reconvened Annual Meeting on October 30, 2026. The proposal sought approval under Nasdaq Listing Rule 5635(d) to issue up to 1,236,668 shares of common stock upon the exercise of warrants issued in an August 10, 2026 inducement transaction. Voting results were 129,795 for and 89,849 against. The company develops biometric authentication solutions.
On September 29, 2026, Bio-Key International entered into Exchange Agreements with Streeterville Capital to partition $416,315.80 of its outstanding Secured Promissory Note into four new notes totaling that amount. The company exchanged these Partitioned Notes for an aggregate of 247,805 shares of common stock, resulting in the Original Note being paid in full. This transaction represents a debt-to-equity swap executed under Section 3(a)(9) of the Securities Act. Bio-Key International operates in the biometric security industry, providing fingerprint and facial recognition solutions.
BIO-KEY International convened its Annual Meeting on September 3, 2026, but adjourned it because stockholders failed to approve Proposal 4, which sought authorization to issue up to 1,236,668 shares of common stock upon exercise of warrants from an August 10, 2026 inducement transaction. The meeting is reconvened for October 2, 2026, at the company's Holmdel, New Jersey offices, with no changes to the proposals or polls. BIO-KEY International operates in the biometric security industry, providing fingerprint and facial recognition authentication solutions.
BIO-key International reported Q2 2026 revenues of $1.9 million, a 13% increase year-over-year, driven by a 53% rise in license fee revenue to $1.2 million. Gross margin improved to 87% from 73%, and the net loss narrowed 51% to $(577K). Approximately $0.8 million in hardware revenue was delayed to H2 2026. The company also raised approximately $2.5 million through a warrant exercise at $4.06 per share, bringing cash reserves above $4.5 million. BIO-key operates in the identity and access management (IAM) and biometric authentication technology industry.
BIO-key International, Inc. entered into a warrant exercise agreement with an existing institutional investor to reduce the exercise price of outstanding warrants from $10.20 to $4.06 per share and issue new unregistered warrants for up to 1,236,668 shares at the same reduced price. The transaction generated approximately $2.51 million in gross proceeds, which the company intends to use for working capital and general corporate purposes, including potential repayment of a secured note. Maxim LLC served as the exclusive placement agent, receiving a 5.0% cash fee. The issuance of new warrants is conditioned on stockholder approval at a meeting to be convened within 120 days, with subsequent meetings every 90 days if necessary. BIO-key International operates in the biometric security industry, providing fingerprint and facial recognition technology solutions.